Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi, Naoya Sakamoto – 6 August 2018 – Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited.

Adam S. Bodzin, Talia B. Baker – 6 August 2018 – Liver transplantation was made a reality through the bravery, innovation, and persistence of Dr. Thomas Starzl. His death in 2017, at the age of 90, makes us pause to consider how far the field has come since its inception by this remarkable pioneer. It also is an opportunity to evaluate the continued novel innovations which contribute to the growth and potential for liver transplantation in the future.

Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi, Naoya Sakamoto – 6 August 2018 – Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Naoki Hiramatsu, Yoshinori Doi, Akira Kaneko, Hideki Hagiwara, Yukinori Yamada, Taizo Hijioka, Masami Inada, Shinji Tamura, Yasuharu Imai, Kunimaro Furuta, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara – 6 August 2018 – Combination treatment of ledipasvir and sofosbuvir (LDV/SOF) is first‐line treatment for patients with chronic hepatitis C genotype 1 in the United States, Europe, and Japan.

Ling Yang, Weijun Wang, Xiaozhan Wang, Jinfang Zhao, Li Xiao, Wenfang Gui, Huiqian Fan, Jing Xia, Zhonglin Li, Jingjing Yan, Afnan Alasbahi, Qingjing Zhu, Xiaohua Hou – 4 August 2018 – Hepatic ischemia/reperfusion (I/R) is a major challenge for liver surgery and specific severe conditions of chronic liver disease. Current surgical and pharmacological strategies are limited to improve liver function after hepatic I/R injury. Thus, an in‐depth understanding of the liver I/R mechanism is pivotal to develop new therapeutic methods.

Saumya Pandey – 4 August 2018

Norihiro Imai, David E. Cohen – 3 August 2018

Noelle M. Gorgis, Curtis Kennedy, Fong Lam, Kathleen Thompson, Jorge Coss‐Bu, Ayse Akcan Arikan, Trung Nguyen, Kathleen Hosek, Tamir Miloh, Saul J. Karpen, Daniel J. Penny, John Goss, Moreshwar S. Desai – 3 August 2018 – Cirrhotic cardiomyopathy (CCM), a comorbidity of end‐stage cirrhotic liver disease, remains uncharacterized in children, largely because of a lack of an established pediatric definition.

Noelle M. Gorgis, Curtis Kennedy, Fong Lam, Kathleen Thompson, Jorge Coss‐Bu, Ayse Akcan Arikan, Trung Nguyen, Kathleen Hosek, Tamir Miloh, Saul J. Karpen, Daniel J. Penny, John Goss, Moreshwar S. Desai – 3 August 2018 – Cirrhotic cardiomyopathy (CCM), a comorbidity of end‐stage cirrhotic liver disease, remains uncharacterized in children, largely because of a lack of an established pediatric definition.

Vinod Arora, Rakhi Maiwall, Vijayaraghavan Rajan, Ankur Jindal, Saggere Muralikrishna Shasthry, Guresh Kumar, Priyanka Jain, Shiv Kumar Sarin – 3 August 2018 – Hepatorenal syndrome (HRS) carries a high short‐term mortality in patients with cirrhosis and acute on chronic liver failure (ACLF). Terlipressin and noradrenaline are routinely used in cirrhosis with HRS and have been found to be equally effective. There are no data comparing the efficacy of terlipressin with noradrenaline in ACLF patients with HRS.